On the evening of April 22, Dajia Weikang released its 2023 financial report and 2024 first quarter report. Last year, the annual revenue was 3.904 billion yuan, and the net profit attributable to the parent company was about 34.3 million yuan. What is the plan for 2024?
Finishing | Hair
01
2023 revenue increased by 18.56% year-on-year
According to the financial report, in 2023, Dajia Weikang will achieve revenue of 3.904 billion yuan, a year-on-year increase of 18.56%, and a net profit attributable to the parent company of 34.2998 million yuan, a year-on-year decrease of 32.85%.
The picture is based on the company's 2023 annual report
The main reason is that the payment of the equity transfer payment of the M&A enterprise has increased the cost of capital, and the M&A company is still in the transition period of closing, and the full delivery and consolidated financial statements have not been completed during the reporting period, resulting in an increase in related costs and expenses, and the second is the company's industrial sector, which will integrate national sales channels and expand the sales team in 2023, resulting in an increase in sales expenses and management expenses.
The picture comes from the company's 2024 first quarter performance report
During the same period, Dajia Weikang disclosed its results for the first quarter of 2024, achieving operating income of 1.28 billion yuan, a year-on-year increase of 46.06%, and net profit attributable to the parent company of 19.44 million yuan, a year-on-year increase of 27.14%.
02
The retail business accounted for 38.56%, with more than 1,400 stores
From the perspective of different sectors, the distribution business has increased steadily, the proportion of retail business has increased year by year, and the advantages of professional pharmacy business have gradually been reflected.
The picture is based on the company's 2023 annual report
Distribution business segment
In 2023, Dajia Weikang will give full play to the advantages of integrated channels, customer advantages and service advantages of batch and zero, extend value-added services to the upstream and downstream of the supply chain, continuously strengthen in-depth strategic cooperation with pharmaceutical manufacturers, strive for the distribution right of varieties purchased in quantity, and at the same time improve the development of blockbuster new products and continue to expand the advantages of varieties. The revenue of pharmaceutical distribution business was 2.301 billion yuan, accounting for 58.95% of the operating income, a year-on-year increase of 1.11%.
Retail Business Segment
As of December 31, 2023, Dajia Weikang has opened a total of 780 pharmacies across the country, including 138 in Hunan, 210 in Hainan, 408 in Ningxia and 24 in Beijing. Up to now, the total number of Dajia Weikang stores has reached more than 1,400.
Dajia Weikang is characterized by chronic disease pharmacy and DTP professional pharmacy. As of the end of the reporting period, 450 DTP products were sold, and the sales volume of DTP was 832 million yuan, an increase of 14.43% over the same period last year, and there were 71 dual-channel pharmacies.
In 2023, the revenue of pharmaceutical retail business will be 1.505 billion yuan, an increase of 51.53% over the same period last year, accounting for 38.56% of the operating income.
Pharmaceutical industry sector
Dajia Weikang currently owns two pharmaceutical companies, Dajia Biopharmaceutical and Tianji Caotang, focusing on the research and development of original chemical drugs, innovative traditional Chinese medicines, first generic drugs, and big health products.
At present, Dajia Biopharma has 63 drug production approvals, including 6 national exclusive varieties (including product specifications), 20 varieties included in the National Medical Insurance Catalog, 12 varieties included in the National Essential Medicines Catalog, 18 OTC (over-the-counter drugs) varieties, and 2 double-span varieties.
The subsidiary, Tianji Caotang, has 20 drug registration approvals, 13 products have entered the national medical insurance catalog, and 3 OTC (over-the-counter drugs) varieties.
Dajia Weikang has integrated the sales teams of Dajia Biopharmaceutical and Tianji Caotang to build a marketing support system. In 2023, the industrial sector will achieve revenue of 75.8491 million yuan, accounting for 1.94% of operating income.
Medical Services Sector
At present, the basic business of the hospital is developing steadily, the management is becoming more and more mature, and the medical service projects of the department are integrated and continue to operate. In 2023, the business income of Jiachen Reproductive Specialist Hospital will be 12.7708 million yuan, accounting for 0.33% of the operating income, an increase of 35.12% over the same period last year.
03
Prospects for the future
In order to achieve the company's future business goals, Dajia Weikang will focus on the following work:
Expand the construction of chain pharmacies by means of new construction and mergers and acquisitions. Dajia Weikang has formed a strategy of taking Hunan as the foundation in the country, developing vertically in the province, and continuously developing to the whole country. In the southern market, Dajia Weikang has rapidly expanded its stores in Hainan Province through self-construction + mergers and acquisitions. In the northern market, the chain acquired by Ningxia is the northern fulcrum, expanding to the surrounding provinces, integrating two wings, and developing to the whole country through the expansion model of "new construction + mergers and acquisitions + franchise".
Based on chain pharmacies, we will create a new model of professional pharmacies in China. With the transformation goal of traditional community pharmacies, it provides professional pharmacy services for surrounding customers, and connects customer health data with pharmacy information platforms and Internet hospitals in real time by adding wearable intelligent medical devices, providing personalized health comprehensive service solutions and creating a new model of professional pharmacies.
Relying on fundraising and investment projects, improve the warehousing and logistics system and improve the ability to respond to services. The company plans to use the Dajia Weikang Pharmaceutical Industry Base project to greatly enhance the company's warehousing, sorting and distribution capabilities, and optimize the logistics structure.
Continue to innovate the service model and develop "Internet +" prescription drug retail. The company continues to innovate the service model, cooperates with more medical institutions, builds an Internet hospital + prescription circulation and sharing platform, and promotes the circulation of prescriptions between hospitals and pharmacies through the interconnection of tripartite information between hospitals, medical insurance and pharmacies, and provides more comprehensive drug information and member health management services.
Focusing on the accumulation of the main business, it empowers the business development of the hospital. Based on the industry accumulation accumulated in serving public hospitals for many years, the company will continue to empower the hospital's business model expansion and business strategy, and actively apply for the review of specialized hospitals, so as to lay a solid foundation for obtaining the practice license of human assisted reproductive technology.
Based on the pharmaceutical industry sector, we will build a national sales team and create independent research and development of core products. The company continues to invest in the research and development of its subsidiaries, upgrades the production technology and process of existing products, comprehensively improves product quality and performance, and enhances product market competitiveness. Through the introduction of excellent marketing and sales teams in the industry, the company continuously optimizes the layout of its own products in the national market, and based on the company's existing pharmaceutical supply chain platform, it is synergistic and integrated with the layout of the pharmaceutical industry, which is conducive to improving the company's comprehensive service capabilities.
END